aripiprazole Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
psychotropics, phenylpiperazine derivatives 242 129722-12-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • aripiprazole hydrate
  • aripiprazole
  • abilify
  • arpizol
  • pripiprazole
  • OPC-14597
A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.
  • Molecular weight: 448.39
  • Formula: C23H27Cl2N3O2
  • CLOGP: 5.31
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 44.81
  • ALOGS: -4.76
  • ROTB: 7
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
15 mg O
15 mg P
13.30 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.56 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 87 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 4.90 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.83 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 75 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
June 4, 2004 EMA
Nov. 15, 2002 FDA OTSUKA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tardive dyskinesia 2219.25 33.86 442 10574 1262 2345807
Weight increased 1661.02 33.86 598 10418 21739 2325330
Maternal exposure during pregnancy 1550.66 33.86 513 10503 14350 2332719
Akathisia 1541.88 33.86 326 10690 1348 2345721
Off label use 1279.46 33.86 710 10306 72888 2274181
Product use in unapproved indication 1076.34 33.86 364 10652 10836 2336233
Psychotic disorder 981.71 33.86 277 10739 4402 2342667
Dystonia 955.25 33.86 232 10784 1962 2345107
Extrapyramidal disorder 949.82 33.86 234 10782 2113 2344956
Dyskinesia 907.93 33.86 262 10754 4527 2342542
Parkinsonism 841.98 33.86 195 10821 1310 2345759
Neuroleptic malignant syndrome 829.49 33.86 205 10811 1875 2345194
Tremor 816.16 33.86 351 10665 20310 2326759
Suicide attempt 812.36 33.86 296 10720 10986 2336083
Treatment noncompliance 725.96 33.86 228 10788 5306 2341763
Mania 671.62 33.86 179 10837 2261 2344808
Suicidal ideation 655.89 33.86 252 10764 10835 2336234
Restlessness 623.42 33.86 194 10822 4369 2342700
Schizophrenia 613.15 33.86 148 10868 1211 2345858
Delusion 565.89 33.86 151 10865 1914 2345155
Somnolence 558.41 33.86 281 10735 23204 2323865
Sedation 553.37 33.86 165 10851 3197 2343872
Anxiety 551.75 33.86 300 10716 29059 2318010
Drug ineffective 539.62 33.86 475 10541 101149 2245920
Completed suicide 527.45 33.86 261 10755 20773 2326296
Agitation 516.55 33.86 212 10804 10839 2336230
Drug interaction 503.86 33.86 282 10734 28881 2318188
Depression 496.81 33.86 276 10740 27856 2319213
Pregnancy 485.22 33.86 185 10831 7764 2339305
Abortion spontaneous 457.28 33.86 206 10810 13239 2333830
Insomnia 441.51 33.86 248 10768 25539 2321530
Electrocardiogram QT prolonged 438.17 33.86 171 10845 7643 2339426
Exposure during pregnancy 405.94 33.86 233 10783 24986 2322083
Hallucination, auditory 401.84 33.86 117 10899 2075 2344994
Intentional overdose 383.35 33.86 173 10843 11148 2335921
Overdose 366.61 33.86 201 10815 19706 2327363
Intentional self-injury 363.53 33.86 126 10890 4001 2343068
Foetal exposure during pregnancy 363.16 33.86 134 10882 5118 2341951
Muscle rigidity 359.03 33.86 103 10913 1728 2345341
Prescribed overdose 350.48 33.86 101 10915 1723 2345346
Gambling disorder 330.36 33.86 66 10950 188 2346881
Prescribed underdose 329.58 33.86 99 10917 1963 2345106
Confusional state 323.85 33.86 199 10817 24145 2322924
Live birth 323.41 33.86 88 10928 1203 2345866
Wrong technique in product usage process 316.30 33.86 182 10834 19566 2327503
Aggression 315.78 33.86 118 10898 4668 2342401
Blood glucose increased 314.95 33.86 155 10861 12135 2334934
Hallucination 309.41 33.86 135 10881 8013 2339056
Blood creatine phosphokinase increased 304.09 33.86 117 10899 5019 2342050
Caesarean section 300.16 33.86 109 10907 3972 2343097
Product use issue 298.54 33.86 149 10867 12020 2335049
Abnormal behaviour 269.56 33.86 105 10911 4655 2342414
Coma 264.57 33.86 125 10891 8931 2338138
Seizure 263.21 33.86 175 10841 24291 2322778
Premature delivery 259.89 33.86 92 10924 3108 2343961
Normal newborn 258.72 33.86 74 10942 1226 2345843
Drug abuse 253.60 33.86 133 10883 11893 2335176
Sexual dysfunction 245.04 33.86 54 10962 278 2346791
Gait disturbance 244.25 33.86 162 10854 22383 2324686
Condition aggravated 242.93 33.86 185 10831 31794 2315275
Salivary hypersecretion 240.50 33.86 69 10947 1156 2345913
Blood prolactin abnormal 239.14 33.86 44 10972 66 2347003
Dysarthria 237.83 33.86 104 10912 6198 2340871
Dysphagia 237.41 33.86 130 10886 12675 2334394
Urinary incontinence 234.81 33.86 92 10924 4141 2342928
Psychiatric symptom 234.10 33.86 63 10953 823 2346246
Toxicity to various agents 232.46 33.86 182 10834 32572 2314497
Fall 230.06 33.86 211 10805 46888 2300181
Serotonin syndrome 225.15 33.86 85 10931 3455 2343614
Rhabdomyolysis 212.69 33.86 98 10918 6606 2340463
Loss of consciousness 198.70 33.86 133 10883 18634 2328435
Musculoskeletal stiffness 193.53 33.86 112 10904 12135 2334934
Muscle twitching 188.99 33.86 70 10946 2695 2344374
Hypotension 187.50 33.86 160 10856 32276 2314793
Hypomania 183.53 33.86 51 10965 756 2346313
Dizziness 182.44 33.86 206 10810 58459 2288610
Anosognosia 181.61 33.86 33 10983 44 2347025
Mental disorder 180.52 33.86 75 10941 3932 2343137
Hyperprolactinaemia 179.79 33.86 49 10967 673 2346396
Psychiatric decompensation 178.74 33.86 39 10977 190 2346879
Psychomotor hyperactivity 178.14 33.86 61 10955 1861 2345208
Oculogyric crisis 176.91 33.86 42 10974 316 2346753
Irritability 173.28 33.86 84 10932 6343 2340726
Abortion induced 170.75 33.86 69 10947 3367 2343702
Diabetes mellitus 166.81 33.86 86 10930 7409 2339660
Vision blurred 165.01 33.86 108 10908 14560 2332509
Hospitalisation 163.78 33.86 108 10908 14745 2332324
Cogwheel rigidity 159.69 33.86 36 10980 209 2346860
Blood prolactin increased 156.61 33.86 48 10968 1019 2346050
Pulmonary embolism 155.88 33.86 113 10903 17970 2329099
Galactorrhoea 155.46 33.86 50 10966 1249 2345820
Tachycardia 154.01 33.86 108 10908 16301 2330768
Social avoidant behaviour 153.57 33.86 41 10975 518 2346551
Urinary retention 153.01 33.86 65 10951 3602 2343467
Economic problem 152.85 33.86 38 10978 354 2346715
Obsessive-compulsive disorder 150.91 33.86 42 10974 626 2346443
Cardio-respiratory arrest 150.74 33.86 86 10930 9060 2338009
Compulsive shopping 150.03 33.86 32 10984 137 2346932
Psychotic symptom 149.38 33.86 33 10983 172 2346897
Gestational diabetes 148.22 33.86 49 10967 1338 2345731
Adverse event 148.07 33.86 80 10936 7579 2339490
Vomiting 143.59 33.86 202 10814 71400 2275669
Disturbance in attention 140.40 33.86 70 10946 5615 2341454
Disturbance in social behaviour 139.78 33.86 31 10985 165 2346904
Catatonia 136.58 33.86 41 10975 809 2346260
Sleep disorder 131.65 33.86 70 10946 6419 2340650
Nausea 131.49 33.86 248 10768 111941 2235128
Hyperhidrosis 127.51 33.86 94 10922 15328 2331741
Hypothermia 127.28 33.86 49 10967 2099 2344970
Abortion 126.44 33.86 39 10977 846 2346223
Cardiac arrest 125.69 33.86 92 10924 14838 2332231
Oedema peripheral 124.64 33.86 111 10905 23652 2323417
Delirium 122.18 33.86 62 10954 5161 2341908
Movement disorder 120.87 33.86 51 10965 2777 2344292
Drooling 120.65 33.86 36 10980 695 2346374
Cognitive disorder 120.44 33.86 62 10954 5319 2341750
Rabbit syndrome 119.50 33.86 23 10993 50 2347019
Stupor 118.27 33.86 35 10981 656 2346413
Anger 116.53 33.86 48 10968 2459 2344610
Logorrhoea 116.23 33.86 32 10984 457 2346612
Drug monitoring procedure incorrectly performed 115.54 33.86 22 10994 44 2347025
Paranoia 114.00 33.86 45 10971 2062 2345007
Depressed mood 113.77 33.86 59 10957 5139 2341930
Constipation 113.35 33.86 101 10915 21528 2325541
Personality change 111.69 33.86 36 10980 905 2346164
Depressed level of consciousness 110.72 33.86 66 10950 7538 2339531
Hypersexuality 108.97 33.86 24 10992 123 2346946
Metabolic disorder 108.82 33.86 32 10984 586 2346483
Impulsive behaviour 105.73 33.86 28 10988 342 2346727
Altered state of consciousness 105.67 33.86 51 10965 3809 2343260
Headache 103.51 33.86 185 10831 79994 2267075
Thinking abnormal 103.40 33.86 41 10975 1901 2345168
Bruxism 102.76 33.86 32 10984 717 2346352
Drug level increased 98.64 33.86 44 10972 2743 2344326
Memory impairment 98.40 33.86 75 10941 12848 2334221
Personality disorder 96.20 33.86 26 10990 345 2346724
Bipolar disorder 96.07 33.86 35 10981 1283 2345786
Threatened labour 95.29 33.86 23 10993 187 2346882
Respiratory arrest 93.54 33.86 55 10961 6123 2340946
Persecutory delusion 93.09 33.86 27 10989 470 2346599
Increased appetite 93.05 33.86 35 10981 1405 2345664
Disinhibition 92.43 33.86 23 10993 215 2346854
Pneumonia aspiration 92.15 33.86 46 10970 3696 2343373
Schizoaffective disorder 91.58 33.86 23 10993 224 2346845
Affective disorder 90.63 33.86 30 10986 822 2346247
Hypokalaemia 90.42 33.86 66 10950 10588 2336481
Suppressed lactation 88.57 33.86 20 10996 117 2346952
Mutism 87.60 33.86 23 10993 271 2346798
Fatigue 87.49 33.86 178 10838 84695 2262374
Underdose 86.51 33.86 52 10964 6026 2341043
Sopor 86.42 33.86 45 10971 3950 2343119
Visual impairment 84.63 33.86 66 10950 11689 2335380
Hypertension 84.63 33.86 96 10920 27265 2319804
Insurance issue 83.95 33.86 24 10992 396 2346673
Vertigo 83.89 33.86 60 10956 9324 2337745
Miosis 83.65 33.86 31 10985 1193 2345876
Emotional distress 83.36 33.86 45 10971 4250 2342819
Syncope 82.86 33.86 76 10940 16799 2330270
Dry mouth 81.29 33.86 56 10960 8197 2338872
Gambling 81.02 33.86 17 10999 66 2347003
Inappropriate affect 80.89 33.86 21 10995 236 2346833
Crying 79.62 33.86 44 10972 4352 2342717
Orthostatic hypertension 78.23 33.86 16 11000 53 2347016
Malaise 77.77 33.86 133 10883 55452 2291617
Muscle spasms 77.69 33.86 82 10934 21484 2325585
Multiple fractures 77.50 33.86 25 10991 630 2346439
Hypertensive crisis 77.34 33.86 36 10980 2477 2344592
Premature labour 76.93 33.86 34 10982 2072 2344997
Generalised tonic-clonic seizure 76.56 33.86 46 10970 5326 2341743
Feeling abnormal 75.06 33.86 84 10932 23497 2323572
Head injury 74.77 33.86 41 10975 3993 2343076
Restless legs syndrome 74.48 33.86 34 10982 2237 2344832
Mood swings 74.10 33.86 38 10978 3231 2343838
Apathy 73.67 33.86 29 10987 1318 2345751
Speech disorder 73.60 33.86 48 10968 6416 2340653
Pyrexia 71.84 33.86 126 10890 53582 2293487
Myoclonus 71.58 33.86 34 10982 2449 2344620
Eye movement disorder 71.39 33.86 27 10989 1100 2345969
Death 71.38 33.86 160 10856 81308 2265761
Hypotonia 69.94 33.86 30 10986 1700 2345369
Hypokinesia 69.54 33.86 30 10986 1724 2345345
Depressive symptom 69.53 33.86 22 10994 520 2346549
Medication error 68.52 33.86 45 10971 6086 2340983
Blepharospasm 67.69 33.86 22 10994 568 2346501
Breast feeding 67.51 33.86 18 10998 226 2346843
Bradycardia 67.45 33.86 54 10962 9927 2337142
Polyuria 66.59 33.86 26 10990 1156 2345913
Acute kidney injury 66.28 33.86 86 10930 28036 2319033
Psychomotor skills impaired 66.26 33.86 20 10996 402 2346667
Eating disorder 65.04 33.86 31 10985 2250 2344819
Mental status changes 64.90 33.86 42 10974 5540 2341529
Enuresis 63.95 33.86 19 10997 361 2346708
Parkinson's disease 63.69 33.86 26 10990 1300 2345769
Cholestasis of pregnancy 63.50 33.86 15 11001 110 2346959
Hallucination, visual 62.84 33.86 33 10983 2946 2344123
Ataxia 62.43 33.86 31 10985 2461 2344608
Balance disorder 62.20 33.86 51 10965 9696 2337373
Asthenia 61.32 33.86 109 10907 46817 2300252
Intentional product misuse 61.29 33.86 50 10966 9439 2337630
Uterine dilation and curettage 61.28 33.86 17 10999 250 2346819
Weight decreased 61.07 33.86 83 10933 28288 2318781
Disease recurrence 61.01 33.86 34 10982 3417 2343652
Muscle tightness 60.83 33.86 28 10988 1877 2345192
Disability 60.28 33.86 22 10994 810 2346259
Dehydration 60.21 33.86 73 10943 22222 2324847
Bankruptcy 60.13 33.86 10 11006 4 2347065
Paradoxical drug reaction 59.85 33.86 19 10997 454 2346615
Hyperphagia 59.77 33.86 17 10999 275 2346794
Cardiometabolic syndrome 58.14 33.86 16 11000 228 2346841
Alopecia 57.73 33.86 71 10945 21930 2325139
Amenorrhoea 56.52 33.86 28 10988 2211 2344858
Palpitations 56.47 33.86 61 10955 16395 2330674
Major depression 55.49 33.86 22 10994 1019 2346050
Hypertonia 55.29 33.86 23 10993 1207 2345862
Sudden death 55.24 33.86 26 10990 1834 2345235
Compulsive sexual behaviour 55.17 33.86 10 11006 13 2347056
Premature baby 55.09 33.86 31 10985 3173 2343896
Myalgia 54.41 33.86 71 10945 23262 2323807
Emotional disorder 54.29 33.86 27 10989 2150 2344919
Lethargy 54.28 33.86 45 10971 8685 2338384
Pregnancy on contraceptive 53.95 33.86 16 11000 302 2346767
Tongue disorder 53.87 33.86 22 10994 1101 2345968
Blood triglycerides increased 53.53 33.86 27 10989 2216 2344853
Electroencephalogram abnormal 53.06 33.86 20 10996 807 2346262
Poisoning deliberate 52.62 33.86 22 10994 1169 2345900
Hyperglycaemia 52.51 33.86 35 10981 4850 2342219
Drug screen false positive 52.43 33.86 15 11001 248 2346821
Swollen tongue 52.00 33.86 36 10980 5307 2341762
Sleep apnoea syndrome 51.93 33.86 26 10990 2100 2344969
Drug hypersensitivity 51.73 33.86 101 10915 46542 2300527
Mental impairment 51.38 33.86 27 10989 2413 2344656
Bradyphrenia 50.92 33.86 21 10995 1078 2345991
Arrhythmia 50.34 33.86 37 10979 5991 2341078
Orthostatic hypotension 49.90 33.86 28 10988 2851 2344218
Affect lability 49.28 33.86 25 10991 2077 2344992
Dyspnoea 49.20 33.86 136 10880 78597 2268472
Anhedonia 49.02 33.86 21 10995 1186 2345883
Sinus tachycardia 48.74 33.86 29 10987 3296 2343773
Sedation complication 48.70 33.86 13 11003 164 2346905
Hyponatraemia 48.55 33.86 51 10965 13274 2333795
Amnesia 48.48 33.86 39 10977 7214 2339855
Trismus 48.27 33.86 19 10997 863 2346206
Binge eating 48.23 33.86 12 11004 112 2346957
Chorioretinopathy 47.98 33.86 14 11002 249 2346820
Reduced facial expression 47.19 33.86 13 11003 186 2346883
Infarction 47.13 33.86 17 10999 605 2346464
Nervousness 45.95 33.86 33 10983 5156 2341913
Decreased appetite 45.52 33.86 73 10943 28818 2318251
Persistent depressive disorder 45.50 33.86 12 11004 144 2346925
Birdshot chorioretinopathy 45.25 33.86 8 11008 8 2347061
Screaming 45.17 33.86 17 10999 683 2346386
Morbid thoughts 44.83 33.86 12 11004 153 2346916
Pancreatitis 44.81 33.86 39 10977 8040 2339029
Neutropenia 44.78 33.86 62 10954 21486 2325583
Tic 44.73 33.86 15 11001 428 2346641
Epilepsy 44.54 33.86 31 10985 4608 2342461
Respiratory failure 44.41 33.86 49 10967 13479 2333590
Treatment failure 44.35 33.86 37 10979 7202 2339867
Parkinsonian rest tremor 44.19 33.86 9 11007 29 2347040
Dysstasia 44.04 33.86 26 10990 2913 2344156
Morning sickness 43.80 33.86 11 11005 107 2346962
Hallucinations, mixed 43.79 33.86 16 11000 591 2346478
Bradykinesia 43.69 33.86 16 11000 595 2346474
Accommodation disorder 43.54 33.86 12 11004 172 2346897
Bipolar I disorder 43.46 33.86 14 11002 351 2346718
Torticollis 43.31 33.86 14 11002 355 2346714
Hostility 43.27 33.86 13 11003 257 2346812
Selective eating disorder 42.94 33.86 14 11002 365 2346704
Impulse-control disorder 42.85 33.86 12 11004 183 2346886
Twin pregnancy 42.71 33.86 13 11003 269 2346800
Incorrect dose administered 42.45 33.86 41 10975 9654 2337415
Poor feeding infant 42.37 33.86 10 11006 73 2346996
Drug withdrawal syndrome 42.07 33.86 35 10981 6786 2340283
Hyperthermia 42.00 33.86 20 10996 1448 2345621
Bundle branch block right 41.96 33.86 17 10999 833 2346236
Gestational hypertension 41.86 33.86 14 11002 396 2346673
Haematoma 41.79 33.86 31 10985 5090 2341979
Decreased activity 41.70 33.86 17 10999 847 2346222
Inappropriate antidiuretic hormone secretion 41.49 33.86 23 10993 2286 2344783
Heart rate increased 41.34 33.86 43 10973 11062 2336007
Obesity 41.13 33.86 20 10996 1516 2345553
Breech presentation 41.05 33.86 13 11003 308 2346761
Hypersomnia 40.97 33.86 23 10993 2343 2344726
Dementia 40.91 33.86 24 10992 2657 2344412
Loss of personal independence in daily activities 40.78 33.86 31 10985 5280 2341789
Wound 40.52 33.86 24 10992 2704 2344365
International normalised ratio abnormal 40.13 33.86 15 11001 591 2346478
Blood pressure increased 40.07 33.86 52 10964 16934 2330135
Agranulocytosis 39.98 33.86 26 10990 3456 2343613
Disorientation 39.93 33.86 33 10983 6339 2340730
Product administered to patient of inappropriate age 39.81 33.86 16 11000 768 2346301
Poisoning 39.79 33.86 24 10992 2796 2344273
Injury 39.76 33.86 32 10984 5922 2341147
Axonal neuropathy 39.76 33.86 11 11005 160 2346909
Agitation neonatal 39.66 33.86 10 11006 99 2346970
Diabetic hyperosmolar coma 39.66 33.86 10 11006 99 2346970
Feeling jittery 39.60 33.86 21 10995 1911 2345158
Alanine aminotransferase increased 39.59 33.86 47 10969 13985 2333084
Gaze palsy 39.58 33.86 13 11003 347 2346722
Parkinsonian gait 39.48 33.86 10 11006 101 2346968
Neuropsychiatric symptoms 38.98 33.86 9 11007 59 2347010
Floppy iris syndrome 38.14 33.86 8 11008 31 2347038
Slow response to stimuli 38.00 33.86 11 11005 190 2346879
Product monitoring error 37.99 33.86 10 11006 119 2346950
Stereotypy 37.99 33.86 10 11006 119 2346950
Inappropriate schedule of product administration 37.99 33.86 43 10973 12161 2334908
Microphthalmos 37.74 33.86 8 11008 33 2347036
Tachyphrenia 37.47 33.86 12 11004 295 2346774
Cyanosis 37.10 33.86 24 10992 3161 2343908
Mydriasis 36.88 33.86 21 10995 2198 2344871
Blood cholesterol increased 36.77 33.86 29 10987 5212 2341857
Product dose omission 36.65 33.86 78 10938 38179 2308890
Drug withdrawal syndrome neonatal 36.54 33.86 13 11003 444 2346625
Product prescribing error 36.20 33.86 23 10993 2937 2344132
Verbal abuse 36.16 33.86 8 11008 42 2347027
Abortion threatened 36.05 33.86 10 11006 147 2346922
Bladder dilatation 35.98 33.86 10 11006 148 2346921
Compulsive hoarding 35.54 33.86 7 11009 18 2347051
Alice in wonderland syndrome 35.27 33.86 7 11009 19 2347050
Acute psychosis 35.20 33.86 13 11003 495 2346574
Personal relationship issue 35.03 33.86 6 11010 4 2347065
Pleurothotonus 34.96 33.86 11 11005 255 2346814
Flat affect 34.72 33.86 11 11005 261 2346808
Hypertonic bladder 34.53 33.86 12 11004 382 2346687
Therapeutic response decreased 34.50 33.86 32 10984 7163 2339906
Hunger 34.35 33.86 14 11002 697 2346372
Rash 34.34 33.86 100 10916 59458 2287611
Premature rupture of membranes 34.29 33.86 15 11001 891 2346178
Unresponsive to stimuli 34.25 33.86 27 10989 4849 2342220
Developmental hip dysplasia 34.21 33.86 10 11006 179 2346890
Euphoric mood 34.06 33.86 15 11001 906 2346163
No adverse event 33.87 33.86 36 10980 9492 2337577

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Neuroleptic malignant syndrome 1307.54 37.16 337 8308 2811 1735325
Akathisia 1169.18 37.16 261 8384 1067 1737069
Tardive dyskinesia 1127.68 37.16 247 8398 905 1737231
Psychotic disorder 1009.65 37.16 305 8340 4751 1733385
Off label use 995.06 37.16 528 8117 38043 1700093
Weight increased 947.19 37.16 355 8290 11002 1727134
Dystonia 866.31 37.16 222 8423 1792 1736344
Extrapyramidal disorder 815.61 37.16 219 8426 2158 1735978
Product use in unapproved indication 696.28 37.16 270 8375 9152 1728984
Delusion 687.84 37.16 189 8456 2042 1736094
Dyskinesia 674.85 37.16 210 8435 3609 1734527
Schizophrenia 647.72 37.16 177 8468 1869 1736267
Drug ineffective 643.35 37.16 482 8163 63319 1674817
Aggression 640.28 37.16 244 8401 7871 1730265
Suicide attempt 622.32 37.16 233 8412 7148 1730988
Parkinsonism 588.72 37.16 151 8494 1218 1736918
Sedation 574.70 37.16 181 8464 3236 1734900
Agitation 548.11 37.16 238 8407 10788 1727348
Blood creatine phosphokinase increased 505.70 37.16 211 8434 8645 1729491
Tremor 492.77 37.16 233 8412 12898 1725238
Mania 460.68 37.16 137 8508 1996 1736140
Somnolence 456.26 37.16 239 8406 16500 1721636
Restlessness 455.42 37.16 161 8484 4160 1733976
Suicidal ideation 449.69 37.16 192 8453 8326 1729810
Foetal exposure during pregnancy 447.01 37.16 176 8469 6183 1731953
Insomnia 442.44 37.16 232 8413 16044 1722092
Gambling disorder 417.77 37.16 91 8554 319 1737817
Hallucination, auditory 409.86 37.16 125 8520 1992 1736144
Treatment noncompliance 404.63 37.16 155 8490 5046 1733090
Anxiety 362.04 37.16 200 8445 15327 1722809
Completed suicide 352.82 37.16 200 8445 16112 1722024
Abnormal behaviour 318.13 37.16 138 8507 6204 1731932
Drug interaction 310.32 37.16 225 8420 27733 1710403
Rhabdomyolysis 309.22 37.16 161 8484 10929 1727207
Muscle rigidity 277.86 37.16 90 8555 1758 1736378
Salivary hypersecretion 272.80 37.16 84 8561 1381 1736755
Hallucination 266.69 37.16 132 8513 8038 1730098
Obsessive-compulsive disorder 263.41 37.16 72 8573 756 1737380
Toxicity to various agents 249.40 37.16 201 8444 28940 1709196
Dysphagia 242.21 37.16 133 8512 10035 1728101
Condition aggravated 238.41 37.16 172 8473 20978 1717158
Priapism 231.10 37.16 74 8571 1390 1736746
Catatonia 226.92 37.16 65 8580 820 1737316
Overdose 223.61 37.16 151 8494 16550 1721586
Psychotic symptom 218.78 37.16 48 8597 175 1737961
Psychomotor hyperactivity 216.30 37.16 75 8570 1818 1736318
Hospitalisation 214.73 37.16 133 8512 12567 1725569
Psychiatric symptom 210.24 37.16 60 8585 746 1737390
Depression 209.60 37.16 145 8500 16524 1721612
Intentional overdose 206.86 37.16 109 8536 7561 1730575
Wrong technique in product usage process 202.98 37.16 120 8525 10415 1727721
Electrocardiogram QT prolonged 200.08 37.16 96 8549 5449 1732687
Musculoskeletal stiffness 197.78 37.16 97 8548 5779 1732357
Hyperhidrosis 191.59 37.16 123 8522 12365 1725771
Seizure 189.62 37.16 148 8497 20293 1717843
Irritability 185.21 37.16 91 8554 5441 1732695
Drooling 184.85 37.16 54 8591 733 1737403
Prescribed overdose 182.59 37.16 65 8580 1705 1736431
Prescribed underdose 181.01 37.16 62 8583 1446 1736690
Confusional state 175.89 37.16 144 8501 21134 1717002
Tachycardia 168.46 37.16 114 8531 12514 1725622
Sleep disorder 163.92 37.16 76 8569 3987 1734149
Pneumonia aspiration 162.59 37.16 82 8563 5184 1732952
Premature baby 160.45 37.16 68 8577 2874 1735262
Blood glucose increased 156.74 37.16 102 8543 10482 1727654
Apathy 154.43 37.16 53 8592 1243 1736893
Persecutory delusion 152.55 37.16 41 8604 401 1737735
Paranoia 151.66 37.16 60 8585 2121 1736015
Serotonin syndrome 150.58 37.16 64 8581 2724 1735412
Speech disorder 146.81 37.16 73 8572 4475 1733661
Dysarthria 145.31 37.16 76 8569 5183 1732953
Muscle twitching 144.55 37.16 55 8590 1747 1736389
Feeling abnormal 137.53 37.16 96 8549 11070 1727066
Vomiting 136.92 37.16 164 8481 38151 1699985
Intentional self-injury 136.57 37.16 59 8586 2614 1735522
Diabetes mellitus 136.39 37.16 80 8565 6828 1731308
Urinary retention 129.48 37.16 71 8574 5324 1732812
Sudden death 128.00 37.16 58 8587 2882 1735254
Libido increased 127.06 37.16 32 8613 236 1737900
Sexual dysfunction 126.21 37.16 50 8595 1773 1736363
Psychiatric decompensation 125.33 37.16 32 8613 251 1737885
Oculogyric crisis 121.93 37.16 33 8612 332 1737804
Increased appetite 120.72 37.16 41 8604 930 1737206
Trismus 120.69 37.16 36 8609 527 1737609
Coma 119.91 37.16 75 8570 7187 1730949
Mental disorder 117.20 37.16 54 8591 2789 1735347
Alanine aminotransferase increased 116.06 37.16 90 8555 12188 1725948
Thinking abnormal 112.30 37.16 42 8603 1270 1736866
Mental impairment 112.22 37.16 47 8598 1926 1736210
Bruxism 112.20 37.16 30 8615 287 1737849
Delirium 110.85 37.16 68 8577 6294 1731842
Altered state of consciousness 109.49 37.16 55 8590 3442 1734694
Dizziness 108.04 37.16 138 8507 34223 1703913
Urinary incontinence 106.66 37.16 50 8595 2686 1735450
Hyperglycaemia 105.05 37.16 61 8584 5104 1733032
Homicidal ideation 104.09 37.16 33 8612 598 1737538
Hiccups 103.95 37.16 41 8604 1436 1736700
Economic problem 103.42 37.16 28 8617 282 1737854
Product administered to patient of inappropriate age 103.42 37.16 35 8610 785 1737351
Blood triglycerides increased 102.86 37.16 48 8597 2552 1735584
Vision blurred 102.69 37.16 72 8573 8351 1729785
Anger 98.65 37.16 47 8598 2619 1735517
Cogwheel rigidity 98.60 37.16 25 8620 190 1737946
Fall 97.89 37.16 117 8528 27097 1711039
Loss of consciousness 96.98 37.16 88 8557 14787 1723349
Depressed level of consciousness 96.21 37.16 63 8582 6529 1731607
Compulsive shopping 94.75 37.16 21 8624 81 1738055
Gambling 94.14 37.16 21 8624 84 1738052
Gait disturbance 92.64 37.16 80 8565 12590 1725546
Restless legs syndrome 92.34 37.16 34 8611 983 1737153
Disturbance in attention 91.42 37.16 52 8593 4182 1733954
Euphoric mood 90.80 37.16 32 8613 813 1737323
Movement disorder 89.03 37.16 38 8607 1632 1736504
Fatigue 88.95 37.16 155 8490 50626 1687510
Social avoidant behaviour 87.42 37.16 29 8616 610 1737526
Hypomania 87.27 37.16 28 8617 528 1737608
Weight decreased 87.06 37.16 101 8544 22652 1715484
Nausea 86.73 37.16 154 8491 51042 1687094
Adverse event 86.71 37.16 52 8593 4616 1733520
Oppositional defiant disorder 85.20 37.16 18 8627 52 1738084
Hypothermia 84.11 37.16 37 8608 1711 1736425
Hepatic function abnormal 82.81 37.16 59 8586 7015 1731121
Myocarditis 81.10 37.16 37 8608 1866 1736270
Bradykinesia 81.05 37.16 26 8619 490 1737646
Obesity 79.61 37.16 31 8614 1048 1737088
Coordination abnormal 79.59 37.16 34 8611 1463 1736673
Maternal exposure during breast feeding 79.05 37.16 24 8621 374 1737762
Tic 78.90 37.16 28 8617 726 1737410
Aspartate aminotransferase increased 78.78 37.16 68 8577 10688 1727448
Disinhibition 78.10 37.16 23 8622 321 1737815
Foetal disorder 77.45 37.16 17 8628 62 1738074
Blood prolactin abnormal 77.41 37.16 16 8629 40 1738096
Cognitive disorder 77.23 37.16 47 8598 4283 1733853
Mydriasis 76.82 37.16 32 8613 1292 1736844
Blood cholesterol increased 75.83 37.16 41 8604 2985 1735151
Lethargy 75.19 37.16 56 8589 7128 1731008
Withdrawal syndrome 74.60 37.16 37 8608 2251 1735885
Therapeutic product effect incomplete 74.48 37.16 50 8595 5398 1732738
Schizoaffective disorder 73.81 37.16 20 8625 202 1737934
Headache 73.66 37.16 115 8530 34261 1703875
Product use issue 72.72 37.16 59 8586 8512 1729624
Affective disorder 72.63 37.16 26 8619 692 1737444
Hyperthermia 72.44 37.16 33 8612 1658 1736478
Drug abuse 72.09 37.16 72 8573 13617 1724519
Drug monitoring procedure incorrectly performed 71.34 37.16 15 8630 42 1738094
Decreased eye contact 71.08 37.16 15 8630 43 1738093
Acute kidney injury 70.87 37.16 114 8531 34830 1703306
Depressed mood 70.42 37.16 39 8606 2977 1735159
Disorientation 69.55 37.16 48 8597 5421 1732715
Hypokinesia 69.45 37.16 29 8616 1178 1736958
Pulmonary embolism 69.35 37.16 69 8576 12990 1725146
Neutropenia neonatal 68.32 37.16 14 8631 33 1738103
Syncope 68.21 37.16 71 8574 14098 1724038
Hypersexuality 68.14 37.16 21 8624 345 1737791
Torticollis 67.66 37.16 20 8625 283 1737853
Antipsychotic drug level below therapeutic 67.42 37.16 18 8627 171 1737965
Generalised tonic-clonic seizure 67.28 37.16 42 8603 4004 1734132
Poor quality sleep 66.49 37.16 28 8617 1162 1736974
Hyponatraemia 66.10 37.16 57 8588 8943 1729193
Breech presentation 66.09 37.16 15 8630 66 1738070
Blood prolactin decreased 65.58 37.16 13 8632 24 1738112
Ataxia 64.93 37.16 34 8611 2319 1735817
Cardio-respiratory arrest 64.52 37.16 57 8588 9236 1728900
Sopor 64.17 37.16 32 8613 1969 1736167
Low birth weight baby 63.73 37.16 25 8620 862 1737274
Cardiometabolic syndrome 63.25 37.16 19 8626 285 1737851
Epilepsy 63.08 37.16 40 8605 3919 1734217
Diabetic ketoacidosis 62.07 37.16 37 8608 3246 1734890
Hepatic steatosis 61.94 37.16 34 8611 2550 1735586
Water intoxication 61.73 37.16 16 8629 134 1738002
Muscle spasms 60.95 37.16 61 8584 11560 1726576
Dysuria 60.76 37.16 38 8607 3634 1734502
Reduced facial expression 60.60 37.16 16 8629 145 1737991
Orthostatic hypotension 60.56 37.16 37 8608 3394 1734742
Pyrexia 60.51 37.16 125 8520 46275 1691861
Dehydration 60.27 37.16 74 8571 17584 1720552
Eye movement disorder 59.84 37.16 24 8621 878 1737258
Depressive symptom 59.52 37.16 19 8626 352 1737784
Gynaecomastia 59.38 37.16 31 8614 2101 1736035
Heat stroke 59.12 37.16 17 8628 217 1737919
Patient restraint 58.87 37.16 11 8634 12 1738124
Blood prolactin increased 58.85 37.16 20 8625 454 1737682
Death 58.76 37.16 183 8462 87260 1650876
Affect lability 58.34 37.16 24 8621 938 1737198
Sydenham's chorea 58.26 37.16 10 8635 3 1738133
Crying 57.61 37.16 27 8618 1448 1736688
Hypernatraemia 57.58 37.16 24 8621 970 1737166
Exposure via breast milk 56.97 37.16 17 8628 249 1737887
Impulsive behaviour 56.89 37.16 20 8625 504 1737632
Bipolar disorder 56.59 37.16 22 8623 740 1737396
Malaise 56.58 37.16 94 8551 29471 1708665
Ventricular septal defect 56.15 37.16 22 8623 756 1737380
Rash 56.12 37.16 109 8536 38584 1699552
Tongue disorder 55.80 37.16 20 8625 534 1737602
Constipation 54.67 37.16 65 8580 14935 1723201
Aspiration 54.40 37.16 28 8617 1842 1736294
Type 2 diabetes mellitus 54.29 37.16 28 8617 1850 1736286
Hallucinations, mixed 54.18 37.16 19 8626 475 1737661
Polydipsia 53.78 37.16 21 8624 715 1737421
Therapeutic response decreased 53.39 37.16 41 8604 5459 1732677
Keratoconus 53.36 37.16 11 8634 27 1738109
Aphasia 52.73 37.16 34 8611 3427 1734709
Exhibitionism 52.14 37.16 10 8635 14 1738122
Psychomotor retardation 51.98 37.16 18 8627 433 1737703
Swollen tongue 51.40 37.16 31 8614 2777 1735359
Hallucination, visual 51.06 37.16 30 8615 2562 1735574
Self-injurious ideation 51.00 37.16 17 8628 363 1737773
Peripheral artery thrombosis 49.77 37.16 17 8628 392 1737744
Medication error 49.67 37.16 37 8608 4706 1733430
Emotional poverty 49.63 37.16 12 8633 73 1738063
Stupor 49.44 37.16 19 8626 619 1737517
Therapeutic product effect variable 49.12 37.16 13 8632 119 1738017
Metabolic disorder 49.08 37.16 18 8627 514 1737622
Neutropenia 49.03 37.16 68 8577 18192 1719944
Gangrene neonatal 48.71 37.16 8 8637 0 1738136
Hyperphagia 48.63 37.16 15 8630 247 1737889
Psychomotor skills impaired 48.11 37.16 16 8629 339 1737797
Heart rate increased 47.32 37.16 41 8604 6469 1731667
Nervousness 47.11 37.16 27 8618 2200 1735936
Anosognosia 46.98 37.16 11 8634 57 1738079
Therapy non-responder 46.63 37.16 40 8605 6226 1731910
Incorrect dose administered 46.60 37.16 43 8602 7366 1730770
Product dose omission 46.51 37.16 74 8571 22366 1715770
Posture abnormal 46.28 37.16 16 8629 383 1737753
Hypovolaemic shock 46.21 37.16 20 8625 888 1737248
Emotional distress 45.80 37.16 25 8620 1853 1736283
Leukopenia 45.35 37.16 45 8600 8435 1729701
Balance disorder 45.09 37.16 38 8607 5774 1732362
Impulse-control disorder 45.01 37.16 15 8630 320 1737816
Leukocytosis 44.89 37.16 31 8614 3502 1734634
Decreased appetite 44.44 37.16 75 8570 23796 1714340
Sudden cardiac death 44.04 37.16 19 8626 837 1737299
Loss of libido 43.60 37.16 18 8627 710 1737426
Soliloquy 43.10 37.16 11 8634 86 1738050
Mood altered 42.95 37.16 25 8620 2097 1736039
Asphyxia 42.83 37.16 20 8625 1063 1737073
Body temperature increased 42.52 37.16 27 8618 2650 1735486
Tearfulness 42.12 37.16 14 8631 296 1737840
Inappropriate antidiuretic hormone secretion 41.89 37.16 23 8622 1725 1736411
Enuresis 41.86 37.16 15 8630 400 1737736
Disability 41.16 37.16 16 8629 538 1737598
Hyperprolactinaemia 41.12 37.16 13 8632 233 1737903
Hyperkinesia 41.07 37.16 13 8632 234 1737902
Muscle contracture 41.02 37.16 13 8632 235 1737901
Vertigo 40.87 37.16 32 8613 4381 1733755
Basilar artery occlusion 40.34 37.16 9 8636 36 1738100
Eating disorder 39.92 37.16 20 8625 1242 1736894
Hepatomegaly 39.90 37.16 22 8623 1663 1736473
Pyramidal tract syndrome 39.78 37.16 10 8635 73 1738063
Staring 39.48 37.16 14 8631 362 1737774
Bankruptcy 39.46 37.16 7 8638 4 1738132
Parkinson's disease 39.22 37.16 22 8623 1720 1736416
Paradoxical drug reaction 39.11 37.16 15 8630 486 1737650
Respiratory arrest 38.89 37.16 35 8610 5804 1732332
Compulsive sexual behaviour 38.88 37.16 9 8636 44 1738092
Energy increased 38.85 37.16 13 8632 281 1737855
Blunted affect 38.65 37.16 10 8635 83 1738053
C-reactive protein increased 38.65 37.16 35 8610 5850 1732286
Anal incontinence 38.43 37.16 19 8626 1147 1736989
Type 1 diabetes mellitus 38.05 37.16 17 8628 815 1737321
Inability to afford medication 37.99 37.16 11 8634 144 1737992
Tachypnoea 37.99 37.16 24 8621 2334 1735802
Drug withdrawal syndrome neonatal 37.80 37.16 16 8629 672 1737464
White blood cell count increased 37.61 37.16 38 8607 7274 1730862
Weight decrease neonatal 37.39 37.16 8 8637 25 1738111
Foetal distress syndrome 37.26 37.16 12 8633 229 1737907
Major depression 37.25 37.16 16 8629 697 1737439

Pharmacologic Action:

SourceCodeDescription
ATC N05AX12 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Other antipsychotics
FDA EPC N0000175430 Atypical Antipsychotic
MeSH PA D000928 Antidepressive Agents
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018492 Dopamine Antagonists
MeSH PA D065127 Dopamine D2 Receptor Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D058825 Serotonin 5-HT1 Receptor Agonists
MeSH PA D058830 Serotonin 5-HT2 Receptor Antagonists
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
MeSH PA D017366 Serotonin Receptor Agonists
CHEBI has role CHEBI:65191 second generation antipsychotic
CHEBI has role CHEBI:37955 H1-receptor antagonist
CHEBI has role CHEBI:35941 serotonergic agonist
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Mixed bipolar I disorder indication 16506000 DOID:3312
Schizophrenia indication 58214004 DOID:5419
Bipolar disorder in remission indication 85248005
Bipolar affective disorder, current episode manic indication 191618007
Infantile autism indication 408857007
Agitation associated with Bipolar Mania indication
Depression Treatment Adjunct indication
Agitation associated with Schizophrenia indication
Suicidal thoughts contraindication 6471006
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Agranulocytosis contraindication 17182001 DOID:12987
Myocardial infarction contraindication 22298006 DOID:5844
Alzheimer's disease contraindication 26929004 DOID:10652
Orthostatic hypotension contraindication 28651003
Conduction disorder of the heart contraindication 44808001
Low blood pressure contraindication 45007003
Chronic heart failure contraindication 48447003
Hyperlipidemia contraindication 55822004 DOID:1168
Cerebrovascular disease contraindication 62914000 DOID:6713
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Leukopenia contraindication 84828003 DOID:615
Tardive dyskinesia contraindication 102449007
Seizure disorder contraindication 128613002
Metabolic syndrome X contraindication 237602007 DOID:14221
Esophageal dysmotility contraindication 266434009 DOID:9192
Neutropenic disorder contraindication 303011007 DOID:1227
At risk for aspiration contraindication 371736008
Impaired cognition contraindication 386806002
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.84 Basic
pKa2 0.67 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 7053092 Jan. 28, 2022 TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8642600 Jan. 28, 2022 TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 7053092 Jan. 28, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9089567 Jan. 28, 2022 TREATMENT OF SCHIZOPHRENIA
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9359302 Sept. 25, 2022 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338428 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8759351 Aug. 6, 2023 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9387182 Dec. 25, 2023 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
9.75MG/1.3ML (7.5MG/ML) ABILIFY OTSUKA N021866 Sept. 20, 2006 DISCN INJECTABLE INTRAMUSCULAR 7115587 July 21, 2024 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8030313 Oct. 19, 2024 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 8338427 March 15, 2025 USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9125939 July 28, 2026 ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8759350 March 2, 2027 ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9444503 Nov. 19, 2027 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8674825 April 9, 2029 METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8956288 July 6, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8945005 Aug. 19, 2029 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8847766 March 29, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 8547248 Dec. 18, 2030 METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9577864 Oct. 3, 2033 METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL 9268909 Oct. 15, 2033 METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR 10525057 March 8, 2034 TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
300MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
300MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
400MG ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Sept. 29, 2014 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
400MG/VIAL ABILIFY MAINTENA KIT OTSUKA PHARM CO LTD N202971 Feb. 28, 2013 RX FOR SUSPENSION, EXTENDED RELEASE INTRAMUSCULAR July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
10MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
15MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
20MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
2MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
30MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
5MG ABILIFY MYCITE KIT OTSUKA PHARM CO LTD N207202 Nov. 13, 2017 RX TABLET ORAL July 27, 2020 NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
10MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
15MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
20MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
2MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
30MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
5MG ABILIFY OTSUKA N021436 Nov. 15, 2002 RX TABLET ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021713 Dec. 10, 2004 DISCN SOLUTION ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
10MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
15MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
20MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
30MG **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** ABILIFY OTSUKA N021729 June 7, 2006 DISCN TABLET, ORALLY DISINTEGRATING ORAL Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S
9.75MG/1.3ML (7.5MG/ML) ABILIFY OTSUKA N021866 Sept. 20, 2006 DISCN INJECTABLE INTRAMUSCULAR Dec. 12, 2021 TREATMENT OF PEDIATRIC PATIENTS WITH TOURETTE'S

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR ANTAGONIST Ki 7.90 WOMBAT-PK CHEMBL
5-hydroxytryptamine receptor 1A GPCR PARTIAL AGONIST Ki 8.15 WOMBAT-PK DRUG LABEL
D(2) dopamine receptor GPCR PARTIAL AGONIST Ki 8.71 WOMBAT-PK CHEMBL
D(4) dopamine receptor GPCR Ki 6.65 WOMBAT-PK
Sodium-dependent dopamine transporter Transporter Ki 5.49 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 5.91 PDSP
5-hydroxytryptamine receptor 3A Ion channel Ki 6.20 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 9.44 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.46 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 5.10 PDSP
D(1B) dopamine receptor GPCR Ki 5.68 PDSP
D(1A) dopamine receptor GPCR Ki 6.06 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5.33 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.42 PDSP
Alpha-2B adrenergic receptor GPCR Ki 6.99 PDSP
Muscarinic acetylcholine receptor M1 GPCR Ki 5.17 PDSP
Alpha-2A adrenergic receptor GPCR Ki 7.13 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 5.63 PDSP
Beta-1 adrenergic receptor GPCR Ki 6.85 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.82 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 5.45 PDSP
5-hydroxytryptamine receptor 2C GPCR Ki 7.36 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 8.53 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 7.24 WOMBAT-PK
5-hydroxytryptamine receptor 1D GPCR Ki 7.20 WOMBAT-PK
Histamine H1 receptor GPCR Ki 7.21 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.69 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 6.51 WOMBAT-PK
Sodium-dependent serotonin transporter Transporter Ki 6.83 WOMBAT-PK
5-hydroxytryptamine receptor 1B GPCR Ki 6.10 WOMBAT-PK
Beta-2 adrenergic receptor GPCR Ki 6.79 PDSP
Sodium-dependent noradrenaline transporter Transporter Ki 5.68 PDSP
Multidrug resistance protein 1 Transporter IC50 6.11 CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 6.22 CHEMBL
D(1A) dopamine receptor GPCR Ki 9.10 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 8.15 CHEMBL
Sodium-dependent serotonin transporter Transporter Ki 5.97 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 9.40 CHEMBL
D(2) dopamine receptor GPCR Ki 9.10 CHEMBL
5-hydroxytryptamine receptor 2C GPCR IC50 7.59 CHEMBL
D(3) dopamine receptor GPCR IC50 7.42 CHEMBL
D(4) dopamine receptor GPCR ANTAGONIST Ki 7.30 IUPHAR
Histamine H1 receptor GPCR Ki 7 CHEMBL
5-hydroxytryptamine receptor 6 GPCR AGONIST Ki 6.80 IUPHAR
5-hydroxytryptamine receptor 7 GPCR AGONIST Ki 7.80 IUPHAR

External reference:

IDSource
D000068180 MESH_DESCRIPTOR_UI
4021367 VUID
N0000148786 NUI
C0299792 UMLSCUI
D01164 KEGG_DRUG
406785006 SNOMEDCT_US
89013 RXNORM
d04825 MMSL
009852 NDDF
17034 MMSL
406784005 SNOMEDCT_US
4021367 VANDF
231328 MMSL
82VFR53I78 UNII
7477 INN_ID
CHEMBL1112 ChEMBL_ID
9SC PDB_CHEM_ID
DB01238 DRUGBANK_ID
CHEBI:31236 CHEBI
34 IUPHAR_LIGAND_ID
60795 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0615-8259 TABLET 5 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6509 TABLET 2 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6510 TABLET 5 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6511 TABLET 10 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6512 TABLET 15 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6513 TABLET 20 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6514 TABLET 30 mg ORAL ANDA 20 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6655 TABLET 2 mg ORAL ANDA 20 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 0904-6656 TABLET 5 mg ORAL ANDA 20 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-216 TABLET 2 mg ORAL ANDA 20 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-217 TABLET 5 mg ORAL ANDA 20 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-218 TABLET 10 mg ORAL ANDA 20 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-219 TABLET 15 mg ORAL ANDA 20 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-220 TABLET 20 mg ORAL ANDA 20 sections
aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 13668-221 TABLET 30 mg ORAL ANDA 20 sections
ABILIFY HUMAN PRESCRIPTION DRUG LABEL 1 16590-323 TABLET 2 mg ORAL NDA 20 sections
ABILIFY HUMAN PRESCRIPTION DRUG LABEL 1 16590-745 TABLET 5 mg ORAL NDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 16714-783 TABLET 2 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 16714-784 TABLET 5 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 16714-785 TABLET 10 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 16714-786 TABLET 15 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 16714-787 TABLET 20 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 16714-788 TABLET 30 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-278 TABLET 2 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-279 TABLET 5 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-280 TABLET 10 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-281 TABLET 15 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-282 TABLET 20 mg ORAL ANDA 20 sections
ARIPIPRAZOLE HUMAN PRESCRIPTION DRUG LABEL 1 16729-283 TABLET 30 mg ORAL ANDA 20 sections
Aripiprazole HUMAN PRESCRIPTION DRUG LABEL 1 17856-0110 SOLUTION 1 mg ORAL ANDA 20 sections